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L E T T E R TO TH E ED I TO R
Bacteremia in cardiac surgery patients with heparin-induced
thrombocytopenia
To the Editor,
We have read with great interest the paper “Characterization of hos-
pitalized cardiovascular patients with suspected heparin-induced
thrombocytopenia” by Stoll et al1 and we found it very important with
a view to clinical prevention.
The authors investigated if the 4T score, a validated score for
prediction of heparin-induced thrombocytopenia (HIT) in surgical
patients, is also suitable for assessing HIT probability in cardiovascu-
lar patients with unclear thrombocytopenia. They found that the 4T
score had a sensitivity of 82.6% and a specificity of 28.6% in their
patients, suggesting that it might not sufficiently predict the clinical
probability of HIT in cardiovascular patients. They also found that
bacteremia was more frequent in patients with non-confirmed HIT,
suggesting infection as a frequent differential diagnosis of thrombo-
cytopenia in these patients (49% vs 17%, P = 0.0185).
With reference to the finding reported in the paper, we
would like to make the following contribution to the discussion.
We retrospectively analyzed data from 600 post-cardiac surgery
patients in order to evaluate the incremental value of performing
4Ts Test and EuroSCORE test for prediction of heparin-induced
thrombocytopenia.2 Anti-PF4/heparin antibodies were tested in
all patients using a commercial immunoassay (Asserachrom H PF4
ELISA kits).3–5 Of the 600 patients investigated, 131 (21.8%)
were found to have anti-PF4/heparin antibodies in the post-
operative period (5-7 days from surgery). The 4Ts score identified
high probability patients that developed anti-PF4/heparin anti-
bodies and had a high number of thrombotic events.2 Among the
several parameters analyzed bacteremia was similar in the two
groups (P = n.s.) and was not associated with an increased risk of
composite cardiovascular events (MACE).
We understand that our post-cardiac surgery patients carry high
risk for bacteremia and this could influence our results.3–6
We agree with Stoll that further research is needed to specify
the risk profile for HIT in different group of cardiovascular
patients.
Informed consent was obtained from all individual participants
included in the study.
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